boswellic acid has been researched along with pioglitazone in 1 studies
| Studies (boswellic acid) | Trials (boswellic acid) | Recent Studies (post-2010) (boswellic acid) | Studies (pioglitazone) | Trials (pioglitazone) | Recent Studies (post-2010) (pioglitazone) |
|---|---|---|---|---|---|
| 227 | 15 | 147 | 4,338 | 824 | 2,277 |
| Protein | Taxonomy | boswellic acid (IC50) | pioglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1 | |
| Bile salt export pump | Rattus norvegicus (Norway rat) | 2 | |
| Peroxisome proliferator-activated receptor gamma | Rattus norvegicus (Norway rat) | 0.7 | |
| Bile salt export pump | Homo sapiens (human) | 0.337 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.114 | |
| Steryl-sulfatase | Homo sapiens (human) | 0.8 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 1.15 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.298 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 3.0379 | |
| Peroxisome proliferator-activated receptor gamma | Mus musculus (house mouse) | 0.7 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 4.8 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 8.65 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelaziz, EZ; Barakat, BM; Bilasy, SE; Farag, NE; Fawzy, MS; Zaitone, SA | 1 |
1 other study(ies) available for boswellic acid and pioglitazone
| Article | Year |
|---|---|
Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.
Topics: Alanine Transaminase; Aldehydes; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Body Weight; Carnitine O-Palmitoyltransferase; Cholesterol; Cyclooxygenase 2; Diet, High-Fat; Disease Models, Animal; Eating; Energy Metabolism; Insulin Resistance; Interleukin-6; Ion Channels; Liver; Male; Mitochondrial Proteins; Nitric Oxide Synthase Type II; Non-alcoholic Fatty Liver Disease; Pioglitazone; Protective Agents; Rats, Wistar; Thiazolidinediones; Triglycerides; Triterpenes; Tumor Necrosis Factor-alpha; Uncoupling Protein 1 | 2015 |